85-6184-45　BRAF35 Polyclonal Antibody 50ul　BT-AP00964

特徴

• 背景：The breast cancer susceptibility gene (BRCA1) localizes to chromosome 17q. Mutations within this gene account for approximately 45% of families with high incidence of breast cancer and at least 80% of families with increased incidence of both early-onset breast cancer and ovarian cancer. A second breast cancer susceptibility gene, BRCA2, located on chromosome 13q12-13, also confers a high incidence of breast cancer, but unlike BRCA1, BRCA2 does not confer a substantially elevated risk of ovarian cancer. The BRCA2-Associated Factor 35 (BRAF35) protein forms a complex with BRCA2, which associates with condensed chromatin during histone H3 phosphorylation. BRAF35 expression levels are highest in proliferating tissues and parallel BRCA2 expression patterns. The structure of BRAF35 includes a kinesin-like coiled coil domain and a nonspecific DNA binding HMG domain. The chromatin localization of BRAF35 and antibody microinjection studies indicate a role for the BRAF35/BRCA2 complex in cell cycle regulation.

仕様

• サイズ：50ul
• 抗原：The antiserum was produced against synthesized peptide derived from human HMG20B. AA range:1-50
• 免疫動物：Rabbit
• 交差性：Human
• 適用：WB, IHC-p, IF, ELISA
• クラス：IgG
• クロナリティ：Polyclonal
• 濃度：1 mg/ml
• 別名：HMG20B; BRAF35; HMGX2; HMGXB2; SMARCE1R; SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily E member 1-related; SMARCE1-related protein; BRCA2-associated factor 35; HMG
• この商品は法規制を確認しておりません。（法規制によって販売できない場合もございます）

• 【試薬に関するお問合せ】
• アズワン株式会社 試薬・プロセス材料グループ
• TEL：06-6447-8641
• FAX：06-6447-8642
• E-mail：[email protected]